Krystal Biotech (KRYS) Return on Capital Employed (2017 - 2026)

Krystal Biotech has disclosed Return on Capital Employed across 10 years of filings, most recently posting 14.21% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 14.21%, up 318.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 14.21% (up 318.0% YoY), and the FY2025 annual result was 14.77%, up 690.0% from the prior year.
• Return on Capital Employed came in at 14.21% for Q1 2026 at Krystal Biotech, up from 13.62% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 14.42% in Q3 2025 to a low of 28.19% in Q1 2023.
• The 5-year median for Return on Capital Employed is 8.56% (2024), against an average of 6.62%.
• Across the five-year window, Return on Capital Employed slumped 1365 bps in 2022 and soared 2401 bps in 2024, its largest moves.
• Krystal Biotech's Return on Capital Employed stood at 26.96% in 2022, then jumped by 47 bps to 14.21% in 2023, then soared by 150 bps to 7.17% in 2024, then soared by 90 bps to 13.62% in 2025, then rose by 4 bps to 14.21% in 2026.
• The last three Return on Capital Employed figures came in at 14.21% (Q1 2026), 13.62% (Q4 2025), and 14.42% (Q3 2025), per Business Quant data.